Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5720577 | 0.82 | MEN1 (0.33) | LMNADRD3PI4KAXDHLRRK2 | |
| SCHEMBL5720237 | 0.80 | LRRK2 (0.31) | PARP1LMNADRD3PI4KAXDH | |
| SCHEMBL130108 | 0.80 | HPGD (0.39) | LMNADRD3PI4KAXDHLRRK2 | |
| SCHEMBL19618145 | 0.78 | HPGD (0.31) | — | |
| SCHEMBL6745188 | 0.77 | HPGD (0.30) | — | |
| SCHEMBL5508786 | 0.76 | CDK2 (0.36) | PARP1 | |
| SCHEMBL2938977 | 0.74 | MKNK1 (0.32) | PARP1 | |
| SCHEMBL19261349 | 0.74 | HTT (0.31) | — | |
| SCHEMBL18879374 | 0.74 | HTT (0.31) | — | |
| SCHEMBL264364 | 0.72 | PI4KA (0.33) | PARP1LMNADRD3PI4KAXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| EP-1925675-B1 | Process for production of nucleoside compound | MITSUI CHEMICALS INC (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-1338654-B1 | PROCESS FOR PRODUCING NUCLEOSIDE COMPOUND | MITSUI CHEMICALS INC (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7381820-B2 | α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside | YAMASA CORPORATION (JP) | 2008-06-03 | — | — | US | disclosed |
| EP-1178051-B1 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | MITSUI CHEMICALS INC (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925675-A1 | Process for production of nucleoside compound | Mitsui Chemicals, Inc. (JP) | 2008-05-28 | — | — | EP | disclosed |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | KOHEL YAMADA, ETAL | 2007-06-14 | — | — | US | disclosed |
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1676853-A1 | ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E | YAMASA CORPORATION (JP) | 2006-07-05 | — | — | EP | disclosed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177201-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-1177202-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2002-02-06 | — | — | EP | disclosed |
| US-6333315-B1 | FOR THERAPY OF AIDS(ACQUIRE IMMUNODEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-12-25 | — | — | US | disclosed |
| US-6291670-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | YAMASA CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000069876-A1 | 4'-C-ETHYNYL PYRIMIDINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000069877-A1 | 4'-C-ETHYNYL PURINE NUCLEOSIDES | YAMASA CORPORATION (JP) | 2000-11-23 | — | — | WO | disclosed |
| US-6103707-A | TREATMENT OF HERPES SIMPLEX VIRUS 1 (HSV-1), HERPES SIMPLEX VIRUS 2 (HSV-2), HUMAN CYTOMEGALOVIRUS (HCMV) AND VARICELLA-ZOSTER VIRUS | YAMASA CORPORATION (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0839813-A1 | 9-(2-DEOXY-2-FLUORO-4-THIO-BETA-D-ARABINOFURANOSYL)PURINE DERIVATIVES | YAMASA CORPORATION (JP) | 1998-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167241-A1 | Method for synthesizing cyclic bisdinucleoside | NSUN2, POLR2H, POLB | PARP1 41/4885CA2 2312/4885CHKA 3766/4885 |
| US-20070135627-A1 | Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside | TYMP, PNP, DUT | PARP1 174/4885CA2 2682/4885CHKA 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.